Breast cancer survivors who were younger, had ER-positive tumors, received aromatase inhibitors alone, or received combined chemotherapy with aromatase inhibitors or tamoxifen had a higher risk of osteopenia and osteoporosis than cancer-free women. This evidence concerns the gene CYP19A1 and osteoporosis.